EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases

Dinesh Thapa, Leon N Warne iD, Marco Falasca iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241914677 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Dinesh Thapa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia. Hauptthemen laut MEDLINE: Cannabis, Cannabinoids, Gastrointestinal Diseases, Hallucinogens. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Little Green Pharma Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Humans have employed cannabis for multiple uses including medicine, recreation, food, and fibre. The various components such as roots, flowers, seeds, and leaves have been utilized to alleviate pain, inflammation, anxiety, and gastrointestinal disorders like nausea, vomiting, diarrhoea, and inflammatory bowel diseases (IBDs). It has occupied a significant space in ethnomedicines across cultures and religions. Despite multi-dimensional uses, the global prohibition of cannabis by the USA through the introduction of the Marijuana Tax Act in 1937 led to prejudice about the perceived risks of cannabis, overshadowing its medicinal potential. Nevertheless, the discovery of tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis, and the endocannabinoid system renewed scientific interest in understanding the role of cannabis in modulating different conditions, including gastrointestinal disorders. Preparations combining cannabidiol and THC have shown promise in mitigating gut symptoms through anti-inflammatory and motility-enhancing effects. This review revisits the ethnomedicinal use of cannabis in gastrointestinal diseases and emphasizes the need for further research to determine optimal dosages, formulations, and safety profiles of cannabis-based medicines. It also underscores the future potential of cannabinoid-based therapies by leveraging the role of the expanded endocannabinoid system, an endocannabinoidome, in the modulation of gastrointestinal ailments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabisCannabinoidsGastrointestinal DiseasesHallucinogensHumansEndocannabinoidsCannabinoid Receptor AgonistsDrug DevelopmentDronabinol

Stichwörter der Autor:innen

G-protein-coupled receptorscannabinoidscannabisendocannabinoid systemendocannabinoidomeethnopharmacologyinflammatory bowel disease

Substanzen

EndocannabinoidsCannabinoidsCannabinoid Receptor AgonistsHallucinogensDronabinol

Autor:innen und Institutionen

  • Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia.
  • Little Green Pharma, West Perth, WA 6872, Australia.

ORCID-Profile: Leon N Warne, Marco Falasca

Förderung

  • Little Green Pharma Ltd.

Zitieren

APA

Thapa, D., Warne, L. N., & Falasca, M. (2023). Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914677

Vancouver

Thapa D, Warne LN, Falasca M. Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914677

BibTeX
@article{Thapa2023,
  author = {Thapa, Dinesh and Warne, Leon N and Falasca, Marco},
  title = {Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241914677}
}
Kostenlos starten →